LIWANLI Innovation Co., Ltd. (3054.TW)
TWD 23.5
(1.29%)
TWD 23.5
(1.29%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.63 Million TWD | -15.62% |
| 2022 | 3.12 Million TWD | 0.48% |
| 2021 | 3.1 Million TWD | -89.09% |
| 2020 | 28.5 Million TWD | 378.42% |
| 2019 | 5.95 Million TWD | 250.94% |
| 2018 | 1.69 Million TWD | 4.81% |
| 2017 | 1.62 Million TWD | -98.4% |
| 2016 | 101.45 Million TWD | -33.23% |
| 2015 | 151.95 Million TWD | -68.94% |
| 2014 | 489.22 Million TWD | 137.02% |
| 2013 | 206.4 Million TWD | -28.29% |
| 2012 | 287.84 Million TWD | 452.8% |
| 2011 | 52.07 Million TWD | 7910.92% |
| 2010 | 650 Thousand TWD | 0.0% |
| 2009 | - TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.61 Million TWD | 31.33% |
| 2024 Q3 | 3.11 Million TWD | 18.88% |
| 2024 Q1 | 1.99 Million TWD | -24.43% |
| 2023 Q2 | 1.89 Million TWD | 4.35% |
| 2023 FY | 2.63 Million TWD | -15.62% |
| 2023 Q1 | 1.81 Million TWD | -41.84% |
| 2023 Q4 | 2.63 Million TWD | 16.38% |
| 2023 Q3 | 2.26 Million TWD | 19.46% |
| 2022 FY | 3.12 Million TWD | 0.48% |
| 2022 Q4 | 3.12 Million TWD | 14.56% |
| 2022 Q3 | 2.72 Million TWD | 119.57% |
| 2022 Q2 | 1.24 Million TWD | -15.4% |
| 2022 Q1 | 1.46 Million TWD | -52.78% |
| 2021 Q1 | 3.21 Million TWD | -88.73% |
| 2021 Q4 | 3.1 Million TWD | 82.24% |
| 2021 Q3 | 1.7 Million TWD | -19.91% |
| 2021 FY | 3.1 Million TWD | -89.09% |
| 2021 Q2 | 2.13 Million TWD | -33.71% |
| 2020 FY | 28.5 Million TWD | 378.42% |
| 2020 Q4 | 28.5 Million TWD | -14.45% |
| 2020 Q3 | 33.32 Million TWD | 6.92% |
| 2020 Q1 | 130.71 Million TWD | 2093.59% |
| 2020 Q2 | 31.16 Million TWD | -76.16% |
| 2019 FY | 5.95 Million TWD | 250.94% |
| 2019 Q4 | 5.95 Million TWD | 117.32% |
| 2019 Q2 | 3.76 Million TWD | 9.34% |
| 2019 Q1 | 3.44 Million TWD | 102.94% |
| 2019 Q3 | 2.74 Million TWD | -27.23% |
| 2018 Q3 | 1.77 Million TWD | 177.19% |
| 2018 Q1 | 566 Thousand TWD | -65.06% |
| 2018 FY | 1.69 Million TWD | 4.81% |
| 2018 Q4 | 1.69 Million TWD | -4.28% |
| 2018 Q2 | 640 Thousand TWD | 13.07% |
| 2017 Q3 | 101 Million TWD | 9880.24% |
| 2017 Q2 | 1.01 Million TWD | -98.76% |
| 2017 Q1 | 81.9 Million TWD | -19.28% |
| 2017 FY | 1.62 Million TWD | -98.4% |
| 2017 Q4 | 1.62 Million TWD | -98.4% |
| 2016 Q1 | 50.99 Million TWD | -66.44% |
| 2016 FY | 101.45 Million TWD | -33.23% |
| 2016 Q4 | 101.45 Million TWD | 6858.71% |
| 2016 Q3 | 1.45 Million TWD | -99.56% |
| 2016 Q2 | 332.66 Million TWD | 552.41% |
| 2015 Q3 | 90.04 Million TWD | -0.03% |
| 2015 Q4 | 151.95 Million TWD | 68.76% |
| 2015 FY | 151.95 Million TWD | -68.94% |
| 2015 Q1 | 151.19 Million TWD | -69.1% |
| 2015 Q2 | 90.07 Million TWD | -40.43% |
| 2014 Q1 | 334.73 Million TWD | 62.18% |
| 2014 Q4 | 489.22 Million TWD | -0.74% |
| 2014 FY | 489.22 Million TWD | 137.02% |
| 2014 Q3 | 492.88 Million TWD | 46.9% |
| 2014 Q2 | 335.52 Million TWD | 0.24% |
| 2013 Q2 | 155.91 Million TWD | -42.5% |
| 2013 Q4 | 206.4 Million TWD | 16.25% |
| 2013 FY | 206.4 Million TWD | -28.29% |
| 2013 Q1 | 271.15 Million TWD | -5.8% |
| 2013 Q3 | 177.55 Million TWD | 13.88% |
| 2012 Q4 | 287.84 Million TWD | 39.87% |
| 2012 Q3 | 205.79 Million TWD | 51.31% |
| 2012 FY | 287.84 Million TWD | 452.8% |
| 2012 Q2 | 136.01 Million TWD | 6.8% |
| 2012 Q1 | 127.35 Million TWD | 144.58% |
| 2011 Q3 | 307.5 Million TWD | 454.62% |
| 2011 Q4 | 52.07 Million TWD | -83.07% |
| 2011 Q2 | 55.44 Million TWD | 8.44% |
| 2011 Q1 | 51.12 Million TWD | 7766.0% |
| 2011 FY | 52.07 Million TWD | 7910.92% |
| 2010 FY | 650 Thousand TWD | 0.0% |
| 2010 Q4 | 650 Thousand TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 192.92 Million TWD | 98.634% |
| Standard Chem & Pharm CO., LTD. | 1.08 Billion TWD | 99.756% |
| Maywufa Company Ltd. | 442.66 Million TWD | 99.405% |
| ScinoPharm Taiwan, Ltd. | 621.1 Million TWD | 99.576% |
| Lotus Pharmaceutical Co., Ltd. | 11.58 Billion TWD | 99.977% |
| YungShin Global Holding Corporation | 1.23 Billion TWD | 99.787% |
| PhytoHealth Corporation | 28.11 Million TWD | 90.624% |
| SCI Pharmtech, Inc. | 1.04 Billion TWD | 99.747% |
| Formosa Laboratories, Inc. | 4.06 Billion TWD | 99.935% |
| PharmaEssentia Corporation | 1.2 Billion TWD | 99.78% |
| Bora Pharmaceuticals Co., LTD. | 5 Billion TWD | 99.947% |